The analysis of price characteristics of monocomponent oral hypoglycemic drugs on the pharmaceutical market of the Republic of Crimea

Introduction. Currently, diabetes mellitus is one of the commonest socially important diseases in the Republic of Crimea. In 2019 the incidence of diabetes mellitus in the population of the Republic amounted to 354.6 per 100 000 people, having outnumbered the figures of the previous year by more than 50%.
Aim. Price analysis of monocomponent oral hypoglycemic drug (OHGD) range offered on the pharmaceutical market of the Republic of Crimea.
Materials and Methods. The object of research conducted during the first half of 2021 was the range of monocomponent OHGDs offered in the pharmaceutical organizations on the territory of the Republic of Crimea. The source of information on the price of single medicinal products (MPs) administered for type 2 diabetes mellitus was the average retail prices of regional specialized pharmacy organizations – the Limited Liability Companies “Apteka Martana” and “Semeinaya Apteka.”
Results.The OHGDs market of the Republic of Crimea is represented by 55 trade names of monocomponent MPs, among which the drugs of biguanide group (16 trade names), sulphonylurea derivatives (29 trade names), dipeptidyl peptidase-4 inhibitors (8 trade names) predominate. The distribution of drugs by country of origin revealed the prevalence of medicinal products of domestic manufacture (73.3%). The price segmentation of monocomponent OHGDs demonstrated the prevalence of MPs of the low price segment.
Conclusion.. The study of monocomponent OHGD range in the pharmacies of the Republic of Crimea enabled to ascertain the high indices of import substitution and the considerable proportion of monocomponent OHDs of the low price segment, which makes the studied group accessible for the patients with type 2 diabetes mellitus.

1. The incidence of socially significant diseases in the population of the Republic of Crimea in 2014–2019 (Data of Ministry of Health of the Republic of Crimea) URL: https://crimea.gks.ru/storage/mediabank/RzcHJhVM/Социально-значимые%20болезни%202014-2019.pdf (accessed 09.12.2021).

2. Shestakova M.V., Vikulova O.K., Zheleznyakova A.V., Isakova M.A., Dedov I.I. Diabetes epidemiology in Russia: what changed over the decade? Therapeutic Arch. 2019;91(10):4–13. doi: 10.26442/00403660.2019.10.000364. (In Russ.)

3. Dedov I.I., Shestakova M.V., Galstyan G.R. The prevalence of type 2 diabetes mellitus in the adult population of Russia (NATION study). Diabetes Mellitus. 2016;19(2):104–112. doi: 10.14341/DM2004116-17.

4. Risk of hypoglycaemia in types 1 and 2 diabetes: effects of treatment modalities and their duration. U.K. Hypoglycaemia Study Group. Diabetologia. 2007;50:1140–1147. doi: 1007/500125-007-0599-y.

5. Anatomical Therapeutic Chemical Classification System (ATC) URL: https://www.vidal.ru/drugs/atc (accessed 09.12.2021).

6. Ambrosio G., De Ferrari G.M., Federici M., Filardi P.P. Safety and tolerability of oral hypoglycemic therapies in type 2 diabetes mellitus patients at high cardiovascular risk. G. Ital. Cardiol. (Rome). 2017;18(6):485–495. doi: 10.1714/2700.27609. (In Italian)

7. Shamkhalova M.Sh., Yarek-Martynova I.Y., Trubitsina N.P., Shestakova M.V. Glucose-lowering therapies in patients with diabetes mellitus and chronic kidney disease. Diabetes Mellitus. 2013;3:97–102. doi: 10.14341/2072-0351-823. (In Russ.)

8. Sheikhmambetova L.N., Egorova S.N., Egorova E.A., Bekirova E.Yu. Market of oral antidiabetic drugs in the Republic of Crimea. Bull. of Contemporary Clin. Medicine. 2021;14(4):35–41. doi: 10.20969/VSKM.2021.14(4).35-41. (In Russ.)

9. Buletova N.E., Kuzibetskaya G.V., Demicheva E.V., Zlochevskiy I.A., Demanchuk S.N. (2014). Research Statistical Methods of Macroeconomic Events: Tutorial. Volgograd. 320 p. (In Russ.)

10. Berezhnaya L.I., Koladov L.V., Tarasenko P.F. (2014). Systematization and Analysis of Statistical Information by Means of Analytical Grouping. Application of Variation Indices in the Analysis of Relationships Socioeconomical Event Signs: Tutorial. Moscow. 30 p. (In Russ.)

11. On approval of standards of medical care for adults with type 2 diabetes mellitus: Order of the Ministry of Health of Russia dated October 1, 2020 No. 1054n. URL: http://docs.cntd.ru/document/566006443 (accessed 09.12.2021).

12. Kotovitskaya A.A., Lobova I.A. Analysis price characteristics of neuroprotective action drugs presented in the pharmaceutical market of Ukraine. Belgorod State University Scientific Bull. Medicine. Pharmacy. 2013;11(154):32–38. (In Russ.)

13. Chupandina E.E., Kurolap M.S. Analysis of economic affordability of medicines for treatment of glaucoma in the pharmaceutical market in Voronezh Region. Belgorod State University Scientific Bull. Medicine. Pharmacy. 2012;10(129):191–196. (In Russ.)

14. On approval of the List of Vital and Essential Drugs in 2020: Government of the Russian Federation Executive Order dated October 12, 2019 No. 2406-r. URL: https://normativ.kontur.ru/document?moduleId=1&documentId=376891 (accessed 09.12.2021).